Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma

Nivolumab, an immune checkpoint inhibitor, is beneficial to patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However, platinum-sensitive R/M-HNSCC has not yet been studied. Hence, in this prospective study, we evaluated the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Isaku, Tsukahara, Kiyoaki, Sato, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821556/
https://www.ncbi.nlm.nih.gov/pubmed/35132165
http://dx.doi.org/10.1038/s41598-022-06084-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821556/
https://www.ncbi.nlm.nih.gov/pubmed/35132165
http://dx.doi.org/10.1038/s41598-022-06084-z

Ejemplares similares